Pfizer: Building The Next Oncology Empire

$43Bn Seagen acquisition positions Pfizer to dominate the $140Bn antibody-drug conjugate market. Numerous potential blockbusters launching pre-2030 should strengthen its oncology portfolio to offse patent cliff impact. Pfizer's 7% yield is well-covered at an 85% FCF payout ratio with a committed dividend growth strategy.